Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR101-80 in Type 2 Diabetes Mellitus
NCT07387003Phase 2Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Feb 2027
- Modality
- Insulin and Analogs
- Countries
- 1
01
Overview
Phase 2, randomised trial of GZR101 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Change in Hemoglobin A1c at 16 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
GZR101
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07387003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387003.